Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Grand Life Sciences Group (Wuhan) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current patent prosecution is concentrated in a single technical division, suggesting a focused approach to their current pharmaceutical filings. This centralized structure allows for a direct and singular focus on one examiner's requirements.
CHEN, PO-CHIH is the busiest examiner for this portfolio, managing 1 pending office action. This single action represents the total pending workload for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution process is centralized, with the outcome of the pending action depending on a single examiner's review. Practitioners should focus on the specific examination patterns of CHEN, PO-CHIH to better navigate the requirements of this pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18131963 | USE OF PENEHYCLIDINE IN TREATMENT OR PREVENTION OF VISION-IMPAIRING EYE DISEASES | CHEN, PO-CHIH | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18131963 | USE OF PENEHYCLIDINE IN TREATMENT OR PREVENTION OF VISION-IMPAIRING EYE DISEASES | CHEN, PO-CHIH | 1621 | §112 | Non-Final OA | 17d overdue | Pending | Apr 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGrand Life Sciences Group (Wuhan) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Po-Chih Chen has the most, with 1 of Grand Life Sciences Group (Wuhan) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
